Galantamine treatment in Alzheimer's disease: Response and long-term outcome in a routine clinical setting

Neuropsychiatric Disease and Treatment

Volumn 7, Issue 1, 2011, Pages 565-576

  Wallin, Åsa K ^a   Wattmo, Carina ^a   Minthon, Lennart ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Alzheimer's disease; Cholinesterase inhibitor; Completion rates; Galantamine; K means cluster analysis; Long term treatment; Routine setting

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANALGESIC AGENT; ANTACID AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANXIOLYTIC AGENT; APOLIPOPROTEIN E4; COBALAMIN; FOLIC ACID; GALANTAMINE; GINKGO BILOBA EXTRACT; MEMANTINE; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; NOOTROPIC AGENT;

ADD ON THERAPY; ADULT; AGED; ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE COGNITIVE SUBSCALE; ARTICLE; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL; CLUSTER ANALYSIS; COGNITION; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISEASE COURSE; DISEASE DURATION; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG WITHDRAWAL; EDUCATION; FEMALE; GENOTYPE; HUMAN; INCIDENCE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; RISK FACTOR; SCORING SYSTEM; UNSPECIFIED SIDE EFFECT;

EID: 80855166582     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/ndt.s24196     Document Type: Article

References (54)

1. Fratiglioni L, Launer LJ, Andersen K, et al. Incidence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurology. 2000;54 Suppl 5:10-15.
2. Fratiglioni L, De Ronchi D, Aguero-Torres H. Worldwide prevalence and incidence of dementia. Drugs Aging. 1999;15:365-375.
3. Christensen K, Doblhammer G, Rau R, Vaupel JW. Ageing populations: the challenges ahead. Lancet. 2009;374:1196-1208.
4. Galasko D, Edland SD, Morris JC, Clark C, Mohs R, Koss E. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): Part XI. Clinical milestones in patients with Alzheimer's disease followed over 3 years. Neurology. 1995;45:1451-1455.
5. Burns A, O'Brien J, Auriacombe S, et al; on behalf of the BAP Dementia Consensus Group. Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. J Psychopharmacol. 2006;20:732-755.
6. Samochocki M, Zerlin M, Jostock R, et al. Galantamine is an allosterically potentiating ligand of the human alpha4/beta2 nAChR. Acta Neurol Scand Suppl. 2000;176:73.
7. Loy C, Schneider L. Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev. 2006;1:CD001747.
8. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology. 2000;5: 2269-2276.
9. Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology. 2000;54:2261-2268.
10. KL, Herrmann N, LouLou MM. Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease. J Psychiatry Neurosci. 2003;28:13-26.
11. Rockwood K, Fay S, Gorman M, Carver D, Graham J. The clinical meaningfulness of ADAS-cog changes in Alzheimer's disease patients treated with donepezil in an open-label trial. BMC Neurology.2007;7:26.
12. Courtney C, Farrell D, Gray R, et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): Randomised doubleblind trial. Lancet. 2004;363:2105-2115.
13. Winblad B, Wimo A, Engedal K, et al. 3-year study of donepezil therapy in Alzheimer's disease: Effects of early and continuous therapy. Dement Geriatr Cogn Disord. 2006;21:353-363.
14. Small GW, Kaufer D, Mendiondo MS, Quarg P, Spiegel R. Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years. Int J Clin Pract. 2005;59:473-477.
15. Pirtilla T, Wilcock G, Truyen L, Damaraju CV. Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicenter trial. Eur J Neurol. 2004;11:734-741.
16. Rogers SL, Doody RS, Pratt RD, Ieni JR. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol. 2000;10: 195-203.
17. Holmes C, Lovestone S. Long-term cognitive and functional decline in late onset Alzheimer's disease: therapeutic implications. Age Aging. 2003;32:200-204.
18. Lyle S, Grizzell M, Willmott S, Benbow S, Clark M, Jolley D. Treatment of a whole population sample of Alzheimer's disease with donepezil over a 4-year period: lessons learned. Dement Geriatr Cogn Disord. 2008;25:226-231.
19. Wallin AK, Gustafson L, Sjogren M, Wattmo C, Minthon L. Five-year outcome of cholinergic treatment of Alzheimer's disease: Early response predicts prolonged time until nursing home placement, but does not alter life expectancy. Dement Geriatr Cogn Disord. 2004;18:197-206.
20. Minthon L, Wallin AK, Eriksson S, Wattmo C, Andreasen N. Long-term rivastigmine treatment in a routine clinical setting. Acta Neurol Scand. 2009;119:180-185.
21. Wallin AK, Andreasen N, Eriksson S, et al. Donepezil in Alzheimer's disease: What to expect after 3 years of treatment in a routine clinical setting. Dement Geriatr Cogn Disord. 2007;23:150-160.
22. American Psychiatric Association. American Psychiatry Association: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition. Washington, DC: American Psychiatric Association; 1994.
23. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.
24. Folstein MF, Folstein S, McHugh PR. "Mini-Mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatry Res. 1975;12:189-198.
25. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141:1356-1364.
26. Lawton MP, Brody EM. Assessment of older people: Self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9:179-186.
27. Knapp MJ, Knopman DS, Solomon PR, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA. 1994;271:985-991.
28. Schneider LS, Olin JT. Clinical global impressions in Alzheimer's clinical trials. Int Psychogeriatr. 1996;8:277-288.
29. Knopman DS, Knapp MJ, Gracon SI, Davis CS. The Clinician Interview- Based Impression (CIBI): A clinician's global change rating scale in Alzheimer's disease. Neurology. 1994;44:2315-2321.
30. Stern R, Mohs R, Davidson M, et al. A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry. 1994;151:390-396.
31. Yesavage JA, Poulsen AB, Sheikh J, Tanke E. Rates of change of common measures of impairment in senile dementia of the Alzheimer's type. Psychopharmacol Bull. 1988;24:531-534.
32. Han L, Cole M, Bellavance F, McCusker J, Primeau F. Tracking cognitive decline in Alzheimer's disease using the Mini-Mental State Examination: a meta-analysis. Int Psychogeriatr. 2000;12: 231-247.
33. Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology. 2001;57:489-495.
34. Doody R, Pavlik V, Massman P, Rountree S, Darby E, Chan W. Predicting progression of Alzheimer's disease. Alzheimers Res Ther. 2010;2:2.
35. Salmon DP, Thal LJ, Butters N, Heindel W. Longitudinal evaluation of dementia of the Alzheimer type: a comparison of 3 standardized mental status examinations. Neurology. 1990;40:1225-1230.
36. Mendiondo MS, Ashford JW, Kryscio RJ, Schmitt FA. Modelling Mini Mental State Examination changes in Alzheimer's disease. Stat Med. 2000;19:1607-1616.
37. Kramer-Ginsberg E, Mohs RC, Aryan M, et al. Clinical predictors of course for Alzheimer patients in a longitudinal study: a preliminary report. Psychopharmacol Bull. 1988;24(3):458-462.
38. Cummings JL. Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations. Am J Geriatr Psychiatry. 2003;11: 131-145.
39. Wilcock G, Howe I, Coles H, et al. A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease. Drugs Aging. 2003;20:777-789.
40. Green RC, Schneider LS, Amato DA, et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease. JAMA. 2009;302:2557-2564.
41. Pakrasi S, Mukaetova-Ladinska EB, McKeith IG, O'Brien JT. Clinical predictors of response to acetyl cholinesterase inhibitors: experience from routine clinical use in Newcastle. Int J Geriatr Psychiatry. 2003;18: 879-886.
42. Farlow MR, Hake A, Messina J, Hartman R, Veach J, Anand R. Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. Arch Neurol. 2001;58: 417-422.
43. Wallin AK, Blennow K, Zetterberg H, Londos E, Minthon L, Hansson O. CSF biomarkers predict a more malignant outcome in Alzheimer disease. Neurology. 2010;74:1531-1537.
44. Rockwood K, Dai D, Mitnitski A. Patterns of decline and evidence of subgroups in patients with Alzheimer's disease taking galantamine for up to 48 months. Int J Geriatr Psychiatry. 2008;23:207-214.
45. Kroger E, van Marum R, Souverein P, Egberts T. Discontinuation of cholinesterase inhibitor treatment and determinants thereof in the Netherlands: A retrospective cohort study. Drugs Aging. 2010;27: 663-675.
46. Rockwood K. Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease. J Neurol Neurosurg Psychiatry.2005;75:677-685.
47. Reynish E, Cortes F, Andrieu S, et al. The ICTUS Study: A prospective longitudinal observational study of 1,380 AD patients in Europe. Neuroepidemiology. 2007;29:29-38.
48. Arbus C, Gardette V, Bui E, et al. Antidepressant use in Alzheimer's disease patients: results of the REAL.FR cohort. Int Psychogeriatr. 2010;22:120-128.
49. Herrmann N, Binder C, Dalziel W, Smyth S, Camacho F. Persistence with cholinesterase inhibitor therapy for dementia: an observational administrative health database study. Drugs Aging. 2009;26: 403-407.
50. Doody RS, Geldmacher DS, Gordon B, et al; for the Donepezil Study Group. Open-label, multicenter, Phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol. 2001;58:427-433.
51. Grossberg G, Irwin P, Satlin A, Mesenbrink P, Spiegel R. Rivastigmine in Alzheimer disease - efficacy over two years. Am J Geriatr Psychiatry.2004;12:420-431.
52. Raschetti R, Maggini M, Sorrentino GC, Martini N, Caffari B, Vanacore N. A cohort study of effectiveness of acetylcholinesterase inhibitors in Alzheimer's disease. Eur J Clin Pharmacol. 2005;61:361-368.
53. Bullock R, Touchon J, Bergman H, et al. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Curr Med Res Opin. 2000;21:1317-1327.
54. Mohs RC, Doody RS, Morris JC, et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology. 2001;5:481-488.